Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Exelixis (EXEL) PT Lowered to $27 at RBC Capital
May 1, 2024 6:30 AM EDTRBC Capital analyst Kennen MacKay lowered the price target on Exelixis (NASDAQ: EXEL) to $27.00 (from $28.00) while maintaining a Outperform rating.
The analyst comments "Cabometyx sales were notably lighter than typical though 1Q softness is a trend (also in '22 & '23) and we... More
Exelixis (EXEL) Misses Q1 EPS by 6c, Misses on Revenue
April 30, 2024 4:14 PM EDTExelixis (NASDAQ: EXEL) reported Q1 EPS of $0.17, $0.06 worse than the analyst estimate of $0.23. Revenue for the quarter came in at $425 million versus the consensus estimate of $456.83 million.
GUIDANCE:
Exelixis sees FY2024 revenue of $1.83-1.93 billion, versus the consensus of $1.91... More
